Robert Stadelman is the Executive Director of Upstream Process Development & Manufacturing, CMC Biologics at Eli Lilly and Company, a role they have held since 2024. Previously, they served as an Executive Director of Upstream Process Development at Loxo Oncology at Lilly and held various scientific positions at companies such as MedImmune, REGENXBIO Inc., and Amgen. Robert earned a Master of Science in Pharmaceutical Bioengineering from the University of Washington, where they achieved a 3.96 GPA, and a Bachelor of Science in Biology from Washington State University.
This person is not in any teams
This person is not in any offices